share_log

12 Health Care Stocks Moving In Wednesday's After-Market Session

12 Health Care Stocks Moving In Wednesday's After-Market Session

週三盤後交易時段,12只醫療保健類股走勢
Benzinga ·  2023/09/13 17:31

Gainers

贏家

  • Infinity Pharmaceuticals (NASDAQ:INFI) shares increased by 23.7% to $0.04 during Wednesday's after-market session. Trading volume for this security closed at 3.2 million, accounting for 94.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.9 million.
  • TransCode Therapeutics (NASDAQ:RNAZ) shares moved upwards by 15.55% to $1.04. The company's market cap stands at $2.1 million.
  • Longeveron Inc. - Subscription Right (NASDAQ:LGVNR) shares increased by 14.94% to $0.01.
  • Scinai Immunotherapeutics (NASDAQ:SCNI) shares increased by 11.45% to $1.46. Today's trading volume for this security ended up closing at 582.8K shares, which is 6319.1 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $5.3 million.
  • Avalo Therapeutics (NASDAQ:AVTX) stock rose 10.86% to $0.25. Trading volume for this security closed at 94.4 million, accounting for 886.9% of its average full-day volume over the last 100 days. The company's market cap stands at $5.0 million.
  • NanoString Technologies (NASDAQ:NSTG) stock rose 10.55% to $1.99. The company's market cap stands at $94.6 million.
  • 無限制藥公司納斯達克股票代碼:INFI)週三盤後上漲23.7%,至0.04美元。這只證券的成交量收於320萬美元,佔過去100天全天平均成交量的94.2%。他們流通股的市值為390萬美元。
  • 代碼轉換治療公司納斯達克股價上漲15.55%,至1.04美元。該公司的市值為210萬美元。
  • Longeveron Inc.-認購權納斯達克(Tmall:LGVNR)股價上漲14.94%,至0.01美元。
  • Scinai免疫療法納斯達克(Sequoia Capital:SCNI)股價上漲11.45%,至1.46美元。該證券今日成交量為582.8K股,是過去100日平均成交量的6319.1%。他們流通股的市值為530萬美元。
  • 阿瓦洛治療公司納斯達克(Tmall:AVTX)股價上漲10.86%,至0.25美元。這只證券的成交量為9,440萬只,佔過去100日全天平均成交量的886.9。該公司的市值為500萬美元。
  • 納米線技術納斯達克(Youku)股價上漲10.55%,至1.99美元。該公司的市值為9460萬美元。

Losers

失敗者

  • Kiromic BioPharma (NASDAQ:KRBP) shares declined by 51.0% to $0.71 during Wednesday's after-market session. At the close, Kiromic BioPharma's trading volume reached 65.0K shares. This is 90.6% of its average volume over the last 100 days.
  • OKYO Pharma (NASDAQ:OKYO) stock decreased by 25.26% to $1.48. At the close, OKYO Pharma's trading volume reached 62.9K shares. This is 26.7% of its average volume over the last 100 days. The company's market cap stands at $37.8 million.
  • Bionomics (NASDAQ:BNOX) stock declined by 22.35% to $1.39. Today's trading volume for this security ended up closing at 226.7K shares, which is 112.6 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $11.3 million.
  • Impel Pharmaceuticals (NASDAQ:IMPL) shares decreased by 12.05% to $0.73. At the close, Impel Pharmaceuticals's trading volume reached 281.1K shares. This is 31.6% of its average volume over the last 100 days. The company's market cap stands at $17.3 million.
  • Creative Medical Tech (NASDAQ:CELZ) stock fell 8.16% to $5.18. This security traded at a volume of 343.5K shares come close, making up 450.3% of its average volume over the last 100 days. The company's market cap stands at $7.4 million.
  • Joint (NASDAQ:JYNT) stock decreased by 7.49% to $8.65. The market value of their outstanding shares is at $126.9 million. The company's, Q2 earnings came out today. See Also:
  • Kiroic BioPharma納斯達克(Sequoia Capital:KRBP)股價週三盤後下跌51.0%至0.71美元。收盤時,Kiroic BioPharma的成交量達到65.0K股。這是過去100天平均成交量的90.6%。
  • 大代藥業(納斯達克:OKYO)股價下跌25.26%,至1.48美元。收盤時,Okyo Pharma的成交量達到62.9萬股。這是其過去100天平均成交量的26.7%。該公司的市值為3780萬美元。
  • 生物學納斯達克(Sequoia Capital)股價下跌22.35%,至1.39美元。該證券今日成交量為226.7K股,是過去100日平均成交量的112.6%。他們流通股的市值為1130萬美元。
  • PEMPL製藥公司(納斯達克:IMPL)股價下跌12.05%,至0.73美元。收盤時,Impel PharmPharmticals的成交量達到281.1K股。這是過去100天平均成交量的31.6%。該公司的市值為1,730萬美元。
  • 創新的醫療技術納斯達克(Sequoia Capital:CELZ)股價下跌8.16%,至5.18美元。這只股票的成交量為343.5K股,接近過去100日平均成交量的450.3%。該公司的市值為740萬美元。
  • 接合納斯達克(JYNT:JYNT)股價下跌7.49%,至8.65美元。他們流通股的市值為1.269億美元。該公司今天公佈了第二季度的收益。另見:

This article was generated by Benzinga's automated content engine and reviewed by an editor.

本文由benzinga的自動內容引擎生成,並由編輯審閱.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論